Synthesis of tetrahydroxybiphenyls and tetrahydroxyterphenyls and their evaluation as amyloid-β aggregation inhibitors

Abstract

3,3′,4,4′-tetrahydroxybiphenyl and three isomeric 3,3″,4,4″-tetrahydroxyterphenyls with varying geometries around the central phenyl ring have been synthesized and evaluated for their in vitro activity against aggregation of Alzheimer’s amyloid-β peptide (Aβ). Results from Congo red spectral-shift assays reveal that all four compounds successfully inhibit association of Aβ monomers. For the tetrahydroxyterphenyls, efficacy varies with linker geometry: the ortho- arrangement affords the most successful inhibition and the para- geometry the least, perhaps due to differing abilities of these compounds to bind Aβ. Of the four small molecules studied, 3,3′,4,4′-tetrahydroxybiphenyl is the most effective inhibitor, reducing Aβ aggregation by 50 percent when present in stoichiometric concentrations.

Conversion of Simple Cyclohexanones into Catechols

“…3,3′,4,4′-Tetrahydroxybiphenyl 3 could inhibit the aggregation of Alzheimer’s amyloid-β peptide (Aβ) . Furthermore, it has been widely used as a ligand for transition metals in coordination chemistry .…”

From Hybrids to New Scaffolds: The Latest Medicinal Chemistry Goals in Multi-target Directed Ligands for Alzheimer’s Disease

“…Several studies have documented the key activity of melatonin in scavenging a variety of reactive oxygen species, and moderate inhibition of A β aggregation affecting the synthesis and maturation of APP [ 289 ], which play an important role in AD. In this line, Wang et al .…”

Cognitive Enhancers (Nootropics). Part 3: Drugs Interacting with Targets other than Receptors or Enzymes. Disease-Modifying Drugs. Update 2014

“…Excellent papers on A␤ aggregation inhibitors from universities were presented: 2013: [535][536][537][538][539][540][541][542], 2014: [543][544][545]922].…”